Literature DB >> 20713025

Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid.

Audrey Gabelle1, Stéphane Roche, Christian Gény, Karim Bennys, Pierre Labauge, Yannick Tholance, Isabelle Quadrio, Laurent Tiers, Baptiste Gor, Chloé Chaulet, Alain Vighetto, Bernard Croisile, Pierre Krolak-Salmon, Jacques Touchon, Armand Perret-Liaudet, Sylvain Lehmann.   

Abstract

Cerebrospinal fluid (CSF) biomarkers are now widely used for diagnosis of Alzheimer disease (AD) in atypical clinical forms, for differential and early diagnosis, or for stratification of patients in clinical trials. Among these biomarkers, different forms of amyloid peptides (Aβ) produced by the cleavage of a transmembrane precursor protein called APP (amyloid precursor protein) have a major role. Aβ peptides exist in different length the most common ones having 40 (Aβ40), 42 (Aβ42), or 38 (Aβ38) amino acids in length. APP processing by gamma-secretase releases also an amino-terminal secreted fragment called sAβPP-beta while an alternative nonamyloidogenic cleavage of APP, through an alpha-secretase, liberates another fragment called sAβPP-alpha. To decipher the molecular and pathological mechanisms leading to the production and the detection of these entities is essential for the comprehension and the prevention of AD. In this report, we present the results of the multiplex measurement of CSF Aβ38, Aβ40, Aβ42, sAβPP-alpha, and sAβPP-beta in 60 patients mostly with dementia eventually segregated between neurochemical dementia diagnostic (NDD) positive and negative groups. The NDD classification was based on our routine Tau, P-tau(181), and Aβ(42) cutoff values. We confirmed previous findings regarding the correlation between sAβPP-alpha and sAβPP-beta, as well as the potential interest of these new biomarkers. We also studied the correlation between sAβPPs and Aβ peptides, as well as between Aβ peptides themselves. We observed a strong correlation between Aβ38 and sAβPP-beta which suggested that the production of this peptide was in direct relation with β secretase activities. We also reported a strong correlation between Aβ38 and Aβ40, while Aβ42 was correlated to these fragments only in nonpathological situations. These results enlighten the complex relationships between these molecular markers in both physiological and pathological situations. Our results are important for the further use of these analytes for AD diagnosis as well as for validating the cell biological hypotheses of APP processing and Aβ fragment production.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713025     DOI: 10.1016/j.brainres.2010.08.022

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  26 in total

Review 1.  Body fluid biomarkers in Alzheimer's disease.

Authors:  Huan Lu; Xi-Chen Zhu; Teng Jiang; Jin-Tai Yu; Lan Tan
Journal:  Ann Transl Med       Date:  2015-04

2.  CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition.

Authors:  Justyna A Dobrowolska; Maria S Michener; Guoxin Wu; Bruce W Patterson; Robert Chott; Vitaliy Ovod; Yuriy Pyatkivskyy; Kristin R Wildsmith; Tom Kasten; Parker Mathers; Mandy Dancho; Christina Lennox; Brad E Smith; David Gilberto; Debra McLoughlin; Daniel J Holder; Andrew W Stamford; Kevin E Yarasheski; Matthew E Kennedy; Mary J Savage; Randall J Bateman
Journal:  J Neurosci       Date:  2014-06-11       Impact factor: 6.167

3.  [The future of biomarkers in dementia diagnostics].

Authors:  R Zimmermann; J Kornhuber; P Lewczuk
Journal:  Nervenarzt       Date:  2011-11       Impact factor: 1.214

4.  CSF sAPPα and sAPPβ levels in Alzheimer's Disease and Multiple Other Neurodegenerative Diseases: A Network Meta-Analysis.

Authors:  Wei Tang; Yan Wang; Juan Cheng; Jie Yao; Yu-You Yao; Qiang Zhou; Shi-He Guan
Journal:  Neuromolecular Med       Date:  2019-08-14       Impact factor: 3.843

Review 5.  Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Anne M Fagan; Richard J Perrin
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

6.  Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease.

Authors:  Mona K Beyer; Guido Alves; Kristy S Hwang; Sona Babakchanian; Kolbjorn S Bronnick; Yi-Yu Chou; Turi O Dalaker; Martin W Kurz; Jan P Larsen; Johanne H Somme; Paul M Thompson; Ole-Bjørn Tysnes; Liana G Apostolova
Journal:  Mov Disord       Date:  2013-02-13       Impact factor: 10.338

7.  New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer's disease.

Authors:  Christiane Rose; Katell Peoc'h; Stéphanie Chasseigneaux; Claire Paquet; Julien Dumurgier; Fanchon Bourasset; Frédéric Calon; Jean-Louis Laplanche; Jacques Hugon; Bernadette Allinquant
Journal:  BMC Neurosci       Date:  2012-07-23       Impact factor: 3.288

Review 8.  Fluid biomarkers in Alzheimer's disease - current concepts.

Authors:  Christoffer Rosén; Oskar Hansson; Kaj Blennow; Henrik Zetterberg
Journal:  Mol Neurodegener       Date:  2013-06-21       Impact factor: 14.195

9.  Protein kinase C-regulated aβ production and clearance.

Authors:  Taehyun Kim; David J Hinton; Doo-Sup Choi
Journal:  Int J Alzheimers Dis       Date:  2011-01-17

10.  Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates.

Authors:  Ezra Mulugeta; Elisabet Londos; Oskar Hansson; Clive Ballard; Ragnhild Skogseth; Lennart Minthon; Kaj Blennow; Henrik Zetterberg; Dag Aarsland
Journal:  Int J Alzheimers Dis       Date:  2011-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.